The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

…, A Marchesoni, H Marzo-Ortega, G Porru… - Annals of the …, 2013 - ard.bmj.com
Objective To develop new composite disease activity indices for psoriatic arthritis (PsA).
Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. …

Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study

…, DD Gladman, A Mathieu, I Olivieri, G Porru… - The Journal of …, 2011 - jrheum.org
Objective. During OMERACT 8, delegates selected patient global assessment (PGA) of
disease as a domain to be evaluated in randomized controlled trials in psoriatic arthritis (PsA). …

Joint and tendon involvement in systemic lupus erythematosus: an ultrasound study of hands and wrists in 108 patients

A Gabba, M Piga, A Vacca, G Porru, P Garau… - …, 2012 - academic.oup.com
Objective. To estimate the prevalence of, and identify factors associated with, hand and
wrist US alterations in a large cohort of SLE patients. Methods. One hundred and eight …

Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia

…, P Sarzi-Puttini, M Montepaone, G Porru… - The Journal of …, 2012 - jrheum.org
Objective. To identify the clinical features that can help to distinguish between psoriatic
arthritis (PsA) and fibromyalgia (FM). Methods. Our cross-sectional study was carried out in 10 …

Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database

…, R Tirri, E Bellis, G Delsante, G Porru… - Clinical and …, 2013 - boa.unimib.it
Objective: To compare drug survival of different anti-TNF drugs (inliximab, INF, etanercept,
ETA, and adalimumab, ADA) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) by …

Optimization of the first eigenvalue in problems involving the 𝑝-Laplacian

F Cuccu, B Emamizadeh, G Porru - Proceedings of the American …, 2009 - ams.org
This paper concerns minimization and maximization of the first eigenvalue in problems
involving the $ p $-Laplacian, under homogeneous Dirichlet boundary conditions. Physically, in …

The arthritis-associated HLA-B* 27: 05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B* 27: 09

…, S Payeli, K McHugh, G Dessole, G Porru… - …, 2013 - academic.oup.com
Objectives. HLA-B*27:05 is associated with AS whereas HLA-B*27:09 is not associated. We
hypothesized that different interactions with KIR immune receptors could contribute to the …

Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study

…, R Scarpa, R Scrivo, R Ramonda, G Porru… - …, 2010 - academic.oup.com
Objective. TNF-α antagonists, infliximab (INF), etanercept (ETA) and adalimumab (ADA), have
been demonstrated to be effective in controlling symptoms in SpAs. The aim of this study …

[PDF][PDF] Nonlinear elastic membranes involving the-Laplacian operator.

F Cuccu, B Emamizadeh, G Porru - Electronic Journal of Differential …, 2006 - eudml.org
This paper concerns an optimization problem related to the Poisson equation for the p− Laplace
operator, subject to homogeneous Dirichlet boundary conditions. Physically the Poisson …

On Monge-Ampère equations with nonlinear gradient terms–Infinite boundary value problems

A Mohammed, G Porru - Journal of Differential Equations, 2021 - Elsevier
The paper investigates the existence, asymptotic boundary behavior and uniqueness of
convex solutions to the Monge-Ampère equation that take infinite values on the boundary of …